Loading...
Market
Market share of donidalorsen among HAE treatments by end of 2024?
5
Resolution / Starting Odds
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Market research reports, healthcare data analytics firms
Story
Ionis Reports Positive Results for Donidalorsen in OASIS-HAE and OASISplus Trials
May 31, 2024, 03:02 PM
Ionis Pharmaceuticals has announced positive results from two late-stage trials, OASIS-HAE and OASISplus, for its investigational therapy donidalorsen in treating hereditary angioedema (HAE). The trials demonstrated that donidalorsen, which targets prekallikrein mRNA, significantly reduced the attack rate in patients compared to a placebo. These benefits were observed even in patients currently on other HAE medications. $IONS (-1.0% pre).
View original story
Similar markets
Amgen's Bkemv dominates • 33%
AstraZeneca retains majority market share • 33%
Other competitors gain significant market share • 34%
Less than 10% • 25%
10% to 25% • 25%
26% to 50% • 25%
More than 50% • 25%
<20% • 25%
20%-40% • 25%
40%-60% • 25%
>60% • 25%
Decrease by more than 10% • 25%
Decrease by less than 10% • 25%
Remain stable • 25%
Increase • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Top 10% • 25%
Top 25% • 25%
Top 50% • 25%
Below 50% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than 30% • 25%
30% to 50% • 25%
51% to 70% • 25%
More than 70% • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Viking Therapeutics • 33%
Madrigal Pharmaceuticals • 33%
GPCR • 33%
Ozempic gains over 30% market share • 25%
Ozempic gains 10-30% market share • 25%
Ozempic gains less than 10% market share • 25%
Ozempic loses market share • 25%